Related Experiment Videos
Primary radiotherapy for localized orbital MALT lymphoma
Quynh Thu Le1, Stephen M Eulau, Tracy I George
1Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305, USA. qle@reyes.stanford.edu
International Journal of Radiation Oncology, Biology, Physics
|February 19, 2002
Summary
Localized orbital MALT lymphoma shows excellent control with radiotherapy. Even after relapse, the disease follows an indolent course, with a recommended dose of 30-30.6 Gy to minimize toxicity.
Area of Science:
- Ophthalmology
- Radiation Oncology
- Hematology
Background:
- Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) can affect the orbit.
- Understanding its natural history and response to radiotherapy is crucial for patient management.
Purpose of the Study:
- To define the natural history, prognosis, and radiocurability of localized orbital MALT lymphoma.
- To evaluate the effectiveness of radiotherapy in treating this condition.
Main Methods:
- Retrospective review of clinical records and pathologic material from 40 patients with orbital lymphoma treated with local radiotherapy.
- Irradiation delivered using electrons (9-20 MeV) or photons (6 MV), with lens shielding.
- Doses ranged from 30-40 Gy, with a mean of 34 Gy.
Main Results:
- 31 cases of orbital MALT lymphoma identified.
- 10-year overall survival was 73% with 100% local control.
- Projected 10-year freedom from relapse was 71%, with most failures occurring in extranodal sites.
Conclusions:
- Localized orbital MALT lymphoma is well-controlled with radiotherapy.
- Orbital MALT lymphoma exhibits an indolent course, even after relapse.
- A reduced radiation dose of 30-30.6 Gy is recommended to minimize late toxicity.